Immunotherapy for Head and Neck Cancer: Biomarkers, Trials, and Transformative Outcomes
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Head and Neck Oncology".
Deadline for manuscript submissions: 28 February 2026 | Viewed by 16
Special Issue Editor
Interests: head and neck cancer; immunotherapy; clinical trial
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Head and neck cancers (HNCs), particularly those driven by viral or environmental etiologies, present complex therapeutic challenges. Immunotherapy has emerged as a transformative treatment approach, especially in recurrent or metastatic settings, with agents like PD-1/PD-L1 inhibitors reshaping the clinical landscape. However, only a subset of patients benefit from immunotherapy, and critical questions remain regarding predictive biomarkers, resistance mechanisms, and how best to integrate immunotherapy with existing modalities.
This Special Issue aims to highlight the current advances and evolving frontiers in immunotherapy for HNCs. We welcome original research, clinical trial updates, and comprehensive reviews on topics including but not limited to the following:
- Biomarkers of response and resistance to immunotherapy;
- The tumor microenvironment and immune landscape of HNC;
- Real-world data and translational studies;
- Novel immunomodulatory agents and vaccine strategies;
- Outcomes and quality-of-life data in the immunotherapy era.
Our goal is to foster a deeper understanding of how immunotherapy can be optimized and personalized for patients with head and neck cancers, ultimately improving long-term outcomes.
Dr. Jong Chul Park
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- head and neck cancer
- biomarkers
- combination therapy
- clinical outcomes
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
